AU2012326682B2 - Method for inhibition of deubiquitinating activity - Google Patents

Method for inhibition of deubiquitinating activity Download PDF

Info

Publication number
AU2012326682B2
AU2012326682B2 AU2012326682A AU2012326682A AU2012326682B2 AU 2012326682 B2 AU2012326682 B2 AU 2012326682B2 AU 2012326682 A AU2012326682 A AU 2012326682A AU 2012326682 A AU2012326682 A AU 2012326682A AU 2012326682 B2 AU2012326682 B2 AU 2012326682B2
Authority
AU
Australia
Prior art keywords
alkyl
compound
phenyl
cancer
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012326682A
Other languages
English (en)
Other versions
AU2012326682A1 (en
Inventor
Rolf Larsson
Stig Linder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vivolux AB
Original Assignee
Vivolux AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivolux AB filed Critical Vivolux AB
Publication of AU2012326682A1 publication Critical patent/AU2012326682A1/en
Application granted granted Critical
Publication of AU2012326682B2 publication Critical patent/AU2012326682B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2012326682A 2011-10-19 2012-10-15 Method for inhibition of deubiquitinating activity Ceased AU2012326682B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE1100776 2011-10-19
SE1100776-2 2011-10-19
SE1200303-4 2012-05-16
SE1200303 2012-05-16
PCT/SE2012/000158 WO2013058691A1 (en) 2011-10-19 2012-10-15 Method for inhibition of deubiquitinating activity

Publications (2)

Publication Number Publication Date
AU2012326682A1 AU2012326682A1 (en) 2014-05-01
AU2012326682B2 true AU2012326682B2 (en) 2016-02-18

Family

ID=48141165

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012326682A Ceased AU2012326682B2 (en) 2011-10-19 2012-10-15 Method for inhibition of deubiquitinating activity

Country Status (21)

Country Link
US (1) US9221761B2 (enExample)
EP (1) EP2780326B1 (enExample)
JP (1) JP6165748B2 (enExample)
KR (1) KR102022575B1 (enExample)
CN (1) CN104271557B (enExample)
AU (1) AU2012326682B2 (enExample)
BR (1) BR112014009365B1 (enExample)
CA (1) CA2852518C (enExample)
CL (1) CL2014000998A1 (enExample)
DK (1) DK2780326T3 (enExample)
EA (1) EA026409B1 (enExample)
ES (1) ES2713484T3 (enExample)
HU (1) HUE041816T2 (enExample)
IL (1) IL232118A (enExample)
MX (1) MX345467B (enExample)
MY (1) MY169330A (enExample)
PL (1) PL2780326T3 (enExample)
PT (1) PT2780326T (enExample)
SG (1) SG11201401608PA (enExample)
WO (1) WO2013058691A1 (enExample)
ZA (1) ZA201403302B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2780326T (pt) * 2011-10-19 2019-03-04 Vivolux Ab Método para inibição da atividade da desubiquitinação
EP2938610A2 (en) 2012-12-28 2015-11-04 The U.S.A. as represented by the Secretary, Department of Health and Human Services Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof
EP3164506A4 (en) * 2014-07-01 2018-02-28 Mayo Foundation for Medical Education and Research Methods and materials for identifying and treating mammals resistant to proteasome inhibitor treatments
GB201416754D0 (en) * 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
MY188957A (en) * 2015-03-30 2022-01-14 Mission Therapeutics Ltd 1-cyano-pyrrolidine compounds as usp30 inhibitors
CN106146542A (zh) * 2015-04-23 2016-11-23 北京大学 姜黄素硼酸衍生物,其制备方法和应用
GB201522768D0 (en) * 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
US10416163B2 (en) * 2016-02-26 2019-09-17 Regents Of The University Of Minnesota Method and treatment of recurring endometrial cancer with an inhibitor of USP14
WO2018140907A1 (en) * 2017-01-30 2018-08-02 Up Therapeutics Inc. Novel spiro and cyclic bis-benzylidine proteasome inhibitor for the treatment of cancer, diabetes and neurological disorders
US12539292B2 (en) 2018-04-01 2026-02-03 Arvinas Operations, Inc. BRM targeting compounds and associated methods of use
CN111956804B (zh) * 2020-07-21 2022-01-07 广州医科大学 Otub1的抑制剂的新应用
CN114959036A (zh) * 2022-06-07 2022-08-30 北京大学 Rpn11标记物在检测骨髓瘤及其患病风险、预后分析及治疗药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007007207A2 (en) * 2005-04-13 2007-01-18 Khairia Youssef Pharmaceutical compositions of 3, 5 -bis (arylidene) -4 -piperidones and analogues there of for modulating cell proliferation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1242379A1 (en) * 1999-12-03 2002-09-25 Emory University Curcumin analogues for treating cancer
EP1572078A4 (en) * 2002-03-08 2006-08-09 Univ Emory NEW CURCUMINOID FACTOR VIIa CONSTRUCTS AS MEANS OF SUPPRESSING TUMOR GROWTH AND ANGIOGENESIS
ATE411300T1 (de) * 2005-08-05 2008-10-15 Hybrigenics Sa Neue cysteine protease hemmers und ihre therapeutische anwendungen
WO2007059613A1 (en) * 2005-11-22 2007-05-31 University Of Saskatchewan Antineoplastic compounds
CA2767808A1 (en) * 2009-07-06 2011-01-13 The Ohio State University Research Foundation Compositions and methods for inhibition of cancers
PT2780326T (pt) * 2011-10-19 2019-03-04 Vivolux Ab Método para inibição da atividade da desubiquitinação

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007007207A2 (en) * 2005-04-13 2007-01-18 Khairia Youssef Pharmaceutical compositions of 3, 5 -bis (arylidene) -4 -piperidones and analogues there of for modulating cell proliferation

Also Published As

Publication number Publication date
EA201490800A1 (ru) 2014-09-30
WO2013058691A1 (en) 2013-04-25
CN104271557B (zh) 2017-12-05
BR112014009365B1 (pt) 2021-08-03
PT2780326T (pt) 2019-03-04
EP2780326A4 (en) 2015-04-22
JP2014530852A (ja) 2014-11-20
CA2852518A1 (en) 2013-04-25
US9221761B2 (en) 2015-12-29
JP6165748B2 (ja) 2017-07-19
DK2780326T3 (en) 2019-03-04
NZ624019A (en) 2016-07-29
MX2014004646A (es) 2014-08-01
EA026409B1 (ru) 2017-04-28
HUE041816T2 (hu) 2019-05-28
ES2713484T3 (es) 2019-05-22
MY169330A (en) 2019-03-21
SG11201401608PA (en) 2014-07-30
KR20140078742A (ko) 2014-06-25
CL2014000998A1 (es) 2014-10-10
US20140228354A1 (en) 2014-08-14
ZA201403302B (en) 2015-05-27
CN104271557A (zh) 2015-01-07
PL2780326T3 (pl) 2019-06-28
IL232118A0 (en) 2014-05-28
KR102022575B1 (ko) 2019-09-18
EP2780326B1 (en) 2018-12-26
AU2012326682A1 (en) 2014-05-01
IL232118A (en) 2016-06-30
CA2852518C (en) 2019-09-24
EP2780326A1 (en) 2014-09-24
MX345467B (es) 2017-02-01
BR112014009365A2 (pt) 2017-04-18
HK1203194A1 (en) 2015-10-23

Similar Documents

Publication Publication Date Title
CA2852518C (en) Azepanone compounds and their use for the inhibition of deubiquitinating activity and the treatment of cancer
Blackburn et al. Potent histone deacetylase inhibitors derived from 4-(aminomethyl)-N-hydroxybenzamide with high selectivity for the HDAC6 isoform
Zhang et al. Targeting p53-MDM2-MDMX loop for cancer therapy
Sosič et al. Cathepsin B inhibitors: Further exploration of the nitroxoline core
MX2008011837A (es) Compuestos de union al dominio de repeticion de inhibidores de proteinas de apoptosis de baculovirus.
US20050203063A1 (en) Proteasome pathway inhibitors and related methods
US20140073668A1 (en) N-quinolin-benzensulfonamides and related compounds for the treatment of cancer, autoimmune disorders and inflammation
WO2008118626A9 (en) Inhibitors of jnk and methods for identifying inhibitors of jnk
JP2018508563A (ja) Usp7阻害剤化合物及び使用方法
Blaquiere et al. Medicinal chemistry of inhibiting RING-type E3 ubiquitin ligases
Xiong et al. Development of potent NEDD8-activating enzyme inhibitors bearing a pyrimidotriazole scaffold
Tasneem et al. Heterocyclic moieties as HDAC inhibitors: role in cancer therapeutics
US9261497B2 (en) Method of treating cancer with modulators of SCFSkp2
Xu et al. Recent advances in the development of Rho kinase inhibitors (2015–2021)
US20130079370A1 (en) Method for the Inhibition of Deubiquitinating Activity
Momose et al. Antitumor effects of tyropeptin‐boronic acid derivatives: New proteasome inhibitors
WO2023131305A1 (zh) Prmt5抑制剂和抗癌治疗剂的组合
SE1200735A1 (sv) Sätt att inhibera deubiqutineringsaktivitet
Li et al. Development of novel PRMT7 inhibitors for the treatment of prostate cancer
NZ624019B2 (en) Method for inhibition of deubiquitinating activity
HK1203194B (en) Method for inhibition of deubiquitinating activity
Mao et al. The ubiquitin-proteasomal system and blood cancer therapy
Bonache de Marcos et al. Highly functionalized β-lactams and 2-ketopiperazines as TRPM8 antagonists with antiallodynic activity
Mendes Internship and Monograph Reports Entitled” Ubiquitin Specific Protease 7 (USP7) Inhibitors as new Agents in Cancer Treatment
Song et al. A Novel Aromatic Amide Derivative SY-65 co-Targeting Tubulin and Histone Deacetylase 1 with Potent Anticancer Activity in Vitro and in Vivo

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired